Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.

@article{Stresing2011NitrogencontainingBC,
  title={Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.},
  author={V. Stresing and P. Fournier and A. Bellahc{\`e}ne and I. Benza{\"i}d and H. M{\"o}nkk{\"o}nen and M. Colombel and F. Ebetino and V. Castronovo and P. Cl{\'e}zardin},
  journal={Bone},
  year={2011},
  volume={48 2},
  pages={
          259-66
        }
}
Nitrogen-containing bisphosphonates (N-BPs) are widely used to block bone destruction associated with bone metastasis because they are effective inhibitors of osteoclast-mediated bone resorption. More specifically, once internalized by osteoclasts, N-BPs block the activity of farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway. In addition to their antiresorptive activity, preclinical evidence shows that N-BPs have antiangiogenic properties. However, the exact reasons… Expand
Bisphosphonates inactivate human EGFRs to exert antitumor actions
Bisphosphonates in preclinical bone oncology.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid
Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.
...
1
2
3
4
...